Tue. 2 Aug 2022, 7:19am ET Benzinga Earnings, News
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.68) per share which missed the analyst consensus estimate of $(2.23) by 20.18 percent. This is a 44.09 percent decrease over losses of $(1.86) per share from the same period last year. The company reported quarterly sales of $36.55 million which missed the analyst consensus estimate of $37.24 million by 1.86 percent. This is a 33.90 percent increase over sales of $27.30 million the same period last year.